专利检索 cpc:"C12Y301/03048" 第 1 页

1.

发明公开
Methods and Materials for Producing Polyols and Electron Rich Compounds 审中-公开

公开(公告)号：US20230416703A1

公开(公告)日：2023-12-28

申请号：US18167711

申请日：2023-02-10

申请人： THE TRUSTEES OF PRINCETON UNIVERSITY

发明人： Yi-Fan Xu , Joshua D. Rabinowitz , Fabien Letisse , Sarah Johnson

IPC分类号： C12N9/16 , C12N1/16 , C12P7/18

CPC分类号： C12N9/16 , C12N1/16 , C12Y301/0305 , C12P7/18 , C12Y301/03048

摘要： Methods and materials for producing polyols are provided comprising recombinant microorganisms expressing a Pyp1 polyol phosphatase. Also provided herein are methods and materials for producing electron rich compounds in recombinant microorganisms lacking the DET1 and/or PHO13 genes.

2.

发明公开
HYPOXIA-RESISTANT NATURAL KILLER CELLS 审中-公开

公开(公告)号：US20230210903A1

公开(公告)日：2023-07-06

申请号：US18000637

申请日：2020-06-02

申请人： ONK THERAPEUTICS LIMITED

发明人： Michael Eamon Peter O'DWYER , Jinsong HU

IPC分类号： A61K35/17 , C12N15/90 , C12N5/0783 , A61P35/00 , C12N9/16

CPC分类号： A61K35/17 , C12N15/90 , C12N5/0646 , A61P35/00 , C12Y301/03048 , C12N9/16 , C12N2510/00

摘要： NK cells and NK cell lines are modified so as to have a more cytotoxic phenotype, namely to have reduced function of Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP-1). Methods of making the modified cells and cell lines, compositions comprising the modified cells and cell lines, as well as uses of said cells, cell lines and compositions in therapy are also provided.

3.

发明申请
CLATHRIN THERAPEUTIC FOR NEUROPSYCHIATRIC DISEASES & DISORDERS 审中-公开

公开(公告)号：US20180256511A1

公开(公告)日：2018-09-13

申请号：US15987568

申请日：2018-05-23

申请人： Franco Vitaliano , Gordana Dragan Vitaliano

发明人： Franco Vitaliano , Gordana Dragan Vitaliano

IPC分类号： A61K9/51 , G01N33/15 , A61K38/46 , A61K38/45 , A61K45/06 , G06N5/02 , G01N35/00 , A61K47/42 , A61K38/17

CPC分类号： A61K9/5169 , A61K38/17 , A61K38/1709 , A61K38/45 , A61K38/465 , A61K45/06 , A61K47/42 , A61K47/62 , A61K47/6949 , A61K49/0004 , B82Y5/00 , B82Y15/00 , B82Y30/00 , C07K14/47 , C07K2319/23 , C12N9/0051 , C12Y205/01018 , C12Y301/03048 , G01N33/15 , G01N35/00722 , G06N5/02 , Y10S977/773 , Y10S977/795 , Y10S977/904 , Y10S977/906 , Y10S977/919 , Y10S977/923 , Y10S977/932

摘要： The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating neuropsychiatric diseases and disorders.

4.

发明授权
Oligonucleotide compositions with enhanced efficiency 有权

公开(公告)号：US10036025B2

公开(公告)日：2018-07-31

申请号：US15724224

申请日：2017-10-03

申请人： Life Technologies Corporation

发明人： Tod Woolf , Margaret Taylor

IPC分类号： C07H21/02 , C07H21/04 , A61K31/70 , C12N15/113 , A61K31/713 , C12N15/11 , C12N5/00

CPC分类号： C12N15/1137 , A61K31/713 , C12N15/111 , C12N15/113 , C12N15/1135 , C12N2310/11 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2320/11 , C12N2320/30 , C12N2320/31 , C12N2320/50 , C12N2330/30 , C12Y207/11022 , C12Y301/03048

摘要： The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.

5.

发明授权
Composition comprising a cell sample from a subject with scoliosis and a reagent for detecting PTPμ or PIPK1y 有权

公开(公告)号：US09989531B2

公开(公告)日：2018-06-05

申请号：US14898904

申请日：2014-06-17

申请人： Chu Sainte-Justine

发明人： Alain Moreau , Marie-Yvonne Akoume Ndong , Mohamed Elbakry

IPC分类号： G01N33/50 , G01N21/53 , C07H21/04 , C07K16/18 , G01N33/573 , G01N33/68 , C12N15/113 , C12Q1/68 , C12Q1/42 , C12Q1/48

CPC分类号： G01N33/573 , C12N15/1137 , C12N2310/14 , C12N2320/30 , C12Q1/42 , C12Q1/485 , C12Q1/6883 , C12Q2600/118 , C12Q2600/158 , C12Y207/01068 , C12Y301/03048 , G01N33/5047 , G01N33/5091 , G01N33/6893 , G01N2333/912 , G01N2333/91215 , G01N2333/916 , G01N2800/10 , G01N2800/50 , G01N2800/56

摘要： Methods of stratifying a subject having or at risk for developing adolescent idiopathic scoliosis (AIS) into diagnostically or clinically useful subclasses are provided. The stratification is based on the subject's PTPμ expression and/or activity and/or PIPK1γ expression and/or activity. Also provided are methods of predicting the risk of developing a scoliosis also based on the subject's PTPμ expression and/or activity and/or PIPK1γ expression and/or activity; and methods of increasing GiPCR signaling in cells of a subject in need thereof comprising administering to the subject's cells an effective amount of an inhibitor of PIPK1γ tyrosine phosphorylation; an activator of PIPK1Y tyrosine dephosphorylation; and/or an inhibitor of PIPK1γ expression and/or activity.

6.

发明申请
NON-HUMAN ANIMALS HAVING A HUMANIZED SIGNAL-REGULATORY PROTEIN GENE 审中-公开

公开(公告)号：US20180139941A1

公开(公告)日：2018-05-24

申请号：US15866632

申请日：2018-01-10

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Andrew J. Murphy , O. Gavin Thurston , Bindu Varghese , Cagan Gurer

IPC分类号： A01K67/027 , C12N15/89 , A61K49/00 , G01N33/50 , C07K14/705 , C12N15/85 , C07K16/28 , C12N15/90 , C12N9/16

CPC分类号： A01K67/0278 , A01K2207/12 , A01K2207/15 , A01K2217/05 , A01K2217/052 , A01K2217/054 , A01K2217/072 , A01K2227/10 , A01K2227/105 , A01K2267/01 , A01K2267/0331 , A01K2267/0381 , A01K2267/0387 , A61K49/0008 , C07K14/70503 , C07K14/70596 , C07K16/2809 , C07K16/2887 , C07K2317/31 , C07K2319/00 , C12N9/16 , C12N15/8509 , C12N15/89 , C12N15/902 , C12N15/907 , C12N2015/8518 , C12N2015/8527 , C12N2015/8572 , C12N2800/30 , C12Y301/03048 , G01N33/5011 , G01N33/5088 , G01N2500/04 , G01N2500/10

摘要： Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRPα gene. Genetically modified mice are described, including mice that express a human or humanized SIRPα protein from an endogenous SIRPα locus.

7.

发明申请
NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR 审中-公开

公开(公告)号：US20180111993A1

公开(公告)日：2018-04-26

申请号：US15568881

申请日：2016-04-26

申请人： UCL BUSINESS PLC

发明人： Martin Pulé , Shaun Cordoba

IPC分类号： C07K16/28 , A61K35/17 , C07K14/705 , C12N9/16 , A61P35/00 , C07K16/30 , C12N7/00

CPC分类号： C07K16/2803 , A61K35/17 , A61K39/0011 , A61K2039/5156 , A61P35/00 , C07K14/70503 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K16/2863 , C07K16/3084 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/033 , C07K2319/04 , C07K2319/05 , C12N7/00 , C12N9/16 , C12N2710/10333 , C12Y301/03048

摘要： The present invention provides a nucleic acid construct comprising the following structure: A-X-B in which X is a nucleic acid sequence which encodes a cleavage site; and A and B are nucleic acid sequences encoding a first and a second chimeric antigen receptor (CAR), each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens; wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain; and wherein: (a) the first and/or second CAR comprises an intracellular retention signal; and/or (b) the signal peptide of the first or second CAR comprises one or more mutation(s) such that it has fewer hydrophobic amino acids.

8.

发明申请
MOLECULAR PROFILING FOR CANCER 审中-公开

公开(公告)号：US20180045727A1

公开(公告)日：2018-02-15

申请号：US15555378

申请日：2016-03-03

申请人： Caris MPI, Inc.

发明人： David SPETZLER , Brian ABBOTT , Philip ELLIS , Sandeep REDDY

IPC分类号： G01N33/574 , G06F19/18 , C12Q1/68

CPC分类号： G01N33/57484 , A61K31/335 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y201/01045 , C12Y201/01063 , C12Y301/03048 , C12Y599/01002 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/5743 , G01N33/57434 , G01N33/57438 , G01N33/57446 , G01N33/57449 , G01N33/5748 , G01N2333/435 , G01N2333/70521 , G01N2333/70532 , G01N2333/70596 , G01N2333/723 , G01N2333/82 , G01N2333/9029 , G01N2333/91017 , G01N2333/916 , G01N2333/99 , G01N2800/52 , G16B20/00

摘要： Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for the disease, such as treatments that provide likely benefit or likely lack of benefit for the disease. The molecular profiling can include analysis of a sequence of a nucleic acid. The invention provides a method of identifying at least one treatment associated with a cancer in a subject. In still another related aspect, the invention provides use of a reagent in carrying out the methods of the invention, and/or use of a reagent in the manufacture of a reagent or kit for carrying out the methods of the invention. In an aspect, the invention provides a system for identifying at least one treatment associated with a cancer in a subject.